Gastroenterology

  • Home
  • Gastroenterology
Headache Relief Shampoo Voted #1 Best New Product in 2019

Dr. D’s Medicated Headache Relief Shampoo is now available. This medicated shampoo will help alleviate headaches simply by soaking it on your head. Finding relief from minor to severe headaches shouldn’t always involve reaching for a bottle of pills. Dr. D is here to give you another option. Our proprietary formula will leave your head feeling better.

BUY NOW! http://headachereliefshampoo.com/product/headache-relief-shampoo/

January 1, 2019 / by / in
A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors
Conditions:   Melanoma;   Breast Carcinoma;   Hepatocellular Carcinoma;   Urothelial Carcinoma;   Squamous Cell Carcinoma of the Head and Neck;   Renal Cell Carcinoma;   Colorectal Carcinoma;   Non-small Cell Lung Carcinoma;   Gastric or Gastroesophageal Junction Adenocarcinoma;   Endometrial Carcinoma;   Mesothelioma;   Neuroendocrine Carcinoma;   Cervical Cancer;   Small Cell Lung Carcinoma;   Squamous Cell Carcinoma of the Anus
Intervention:   Biological: XmAb20717
Sponsors:   Xencor, Inc.;   ICON plc
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

October 18, 2019 / by / in
The Gastric Cancer Foundation: A Gastric Cancer Registry
Condition:   Gastric Cancer
Intervention:  
Sponsor:   Stanford University
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

October 18, 2019 / by / in
Efficacy and Safety of Cannabidiol for Gastroparesis and Functional Dyspepsia
Conditions:   Gastroparesis;   Dyspepsia
Interventions:   Drug: Cannabidiol;   Other: placebo
Sponsor:   Mayo Clinic
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

October 17, 2019 / by / in
Trial of mFOLFOX6 + Trastuzumab + Avelumab in Gastric and Esophageal Adenocarcinomas
Conditions:   Gastric Adenocarcinoma;   Esophageal Adenocarcinoma;   Metastasis;   HER-2 Gene Amplification
Interventions:   Drug: Oxaliplatin;   Drug: Leucovorin;   Drug: 5 fluorouracil;   Drug: Trastuzumab;   Drug: Avelumab
Sponsors:   Michael Sangmin Lee;   EMD Serono;   University of North Carolina, Chapel Hill
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

October 16, 2019 / by / in
A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis 01
Conditions:   Gastroparesis;   Diabetes Mellitus
Interventions:   Drug: Relamorelin;   Drug: Placebo
Sponsor:   Allergan
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

October 11, 2019 / by / in
Pembrolizumab, Combination Chemotherapy, and Radiation Therapy Before Surgery in Treating Adult Patients With Locally Advanced Gastroesophageal Junction or Gastric Cardia Cancer That Can Be Removed by Surgery
Conditions:   Gastric Cardia Adenocarcinoma;   Gastroesophageal Junction Adenocarcinoma;   Stage IB Gastric Cancer AJCC v7;   Stage II Gastric Cancer AJCC v7;   Stage IIA Gastric Cancer AJCC v7;   Stage IIB Gastric Cancer AJCC v7;   Stage IIIA Gastric Cancer AJCC v7;   Stage IIIB Gastric Cancer AJCC v7
Interventions:   Drug: Carboplatin;   Procedure: Computed Tomography;   Drug: Fluorouracil;   Other: Laboratory Biomarker Analysis;   Drug: Leucovorin Calcium;   Drug: Oxaliplatin;   Drug: Paclitaxel;   Biological: Pembrolizumab;   Procedure: Positron Emission Tomography;   Radiation: Radiation Therapy;   Procedure: Therapeutic Conventional Surgery
Sponsors:   Mayo Clinic;   National Cancer Institute (NCI)
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

October 11, 2019 / by / in
Trial of IW-3718 for 8 Weeks in Patients With Persistent Gastroesophageal Reflux Disease (GERD) Receiving Proton Pump Inhibitors
Condition:   Gastroesophageal Reflux Disease (GERD)
Interventions:   Drug: IW-3718;   Drug: placebo
Sponsor:   Ironwood Pharmaceuticals, Inc.
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

October 11, 2019 / by / in
Detection of Gastrointestinal Bleeding in Intensive Care Patients Via Biosensor Watch
Condition:   Gastro Intestinal Bleeding
Intervention:   Device: E4 wristband
Sponsor:   Columbia University
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

October 2, 2019 / by / in
Combination Margetuximab, INCMGA00012, MGD013, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer (MAHOGANY)
Conditions:   Gastric Cancer;   Gastroesophageal Junction Cancer;   HER2-positive Gastric Cancer
Interventions:   Combination Product: margetuximab plus INCMGA00012;   Combination Product: Margetuximab plus INCMGA00012 plus chemo;   Combination Product: Margetuximab plus MGD013 plus chemo;   Combination Product: Margetuximab plus chemo;   Combination Product: Trastuzumab plus chemo
Sponsors:   MacroGenics;   Zai Lab (Shanghai) Co., Ltd.
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

October 2, 2019 / by / in
Cabozantinib in Combination With Durvalumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies (CAMILLA)
Conditions:   Gastric Cancer;   Esophageal Adenocarcinoma;   Hepatocellular Carcinoma;   Colorectal Cancer
Interventions:   Drug: Cabozantinib;   Drug: Durvalumab
Sponsors:   Anwaar Saeed;   AstraZeneca;   Exelixis
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

October 1, 2019 / by / in